Kymera Therapeutics, Inc. (KYMR)
87.04
+0.54
(+0.62%)
USD |
NASDAQ |
Feb 20, 12:28
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.262B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 129.7% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 163.14 |
| Price to Book Value | 6.618 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0888 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 87.51% |
Profile
| Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA. |
| URL | http://www.kymeratx.com |
| Investor Relations URL | https://investors.kymeratx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 26, 2026 |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA. |
| URL | http://www.kymeratx.com |
| Investor Relations URL | https://investors.kymeratx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 26, 2026 |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |